Furthermore, compound 5c inhibited the CYP17 enzyme in mice prostate cancer models at concentrations ranging from 35.50 to 15.80 nM and was nearly equipotent to abiraterone in decreasing plasma testosterone levels in prostate cancer-treated mice. Here, CYP17A1 is linked to prostate carcinoma.